|
| |
Neurocrine BiosciencesNeurocrine Biosciences is a leading neuroscience company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The Company'sneuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, Alzheimer's disease, insomnia, stroke, glioblastoma, multiple sclerosis, obesity and diabetes.
| Contact Details: |
| 12790 El Camino Real |
| San Diego |
| CA |
| 92130 |
| United States of America |
| Tel: | 858/617-7600 |
| Fax: | 858/617-7601 |
| Email: | ir@neurocrine.com |
| WWW: | www.neurocrine.com/home.html
|
|
Loading...
|
Recent Publications by Neurocrine Biosciences: |  |
Characterization of novel selective H1-antihistamines for clinical evaluation in the treatment of insomnia.
Analogues of the known H(1)-antihistamine R-dimethindene were profiled as... | 26th September, 2009
| Neurocrine Biosciences, 12780 El Camino Real, San Diego, California 92130,
| J Med Chem. 2009 Sep 10;52(17):5307-10.
DOI Direct Link |
Validation and application of a liquid chromatography-tandem mass spectrometric method for the simultaneous determination of testosterone and dihydrotestosterone in rat prostatic tissue using a 96-well format.
A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was... | 22nd September, 2009
| Neurocrine Biosciences Inc., 12780 El Camino Real, San Diego, CA 92130,
| J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Nov 1;877(29):3515-21.
DOI Direct Link |
Analytical method for simultaneously measuring ex vivo drug receptor occupancy and dissociation rate: application to (R)-dimethindene occupancy of central histamine H1 receptors.
We introduce a novel experimental method to determine both the extent of... | 22nd August, 2009
| Division of Emerging New Technologies, Neurocrine Biosciences, San Diego,
| J Recept Signal Transduct Res. 2009;29(2):84-93.
DOI Direct Link |
Brain-penetrating 2-aminobenzimidazole H(1)-antihistamines for the treatment of insomnia.
The benzimidazole core of the selective non-brain-penetrating... | 26th June, 2009
| Neurocrine Biosciences, 12780 El Camino Real, San Diego, CA 92130, USA.
| Bioorg Med Chem Lett. 2009 Aug 1;19(15):4380-4. Epub 2009 May 27.
DOI Direct Link |
A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.
AIMS: To evaluate the pharmacokinetics (PK) of five H(1) receptor... | 16th June, 2009
| Neurocrine Biosciences,
| Br J Clin Pharmacol. 2009 Mar;67(3):288-98.
DOI Direct Link |
→View more Neurocrine Biosciences research publications. |
Press Releases on Neurocrine Biosciences:
|
 |
| Neurocrine Biosciences Reports Third Quarter 2009 Results |
28th October, 2009 |
Neurocrine Biosciences, Inc. |
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2009. For the third quarter of 2009,
|
| Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results |
23rd October, 2009 |
Neurocrine Biosciences, Inc. |
SAN DIEGO, Oct. 23 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report its third quarter 2009 financial results after the Nasdaq market
|
| Neurocrine Biosciences Amends Corporate Headquarters Lease |
1st October, 2009 |
Neurocrine Biosciences, Inc. |
SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company has entered into an amendment to its facility lease agreement. The amendment
|
| Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference |
16th September, 2009 |
Neurocrine Biosciences, Inc. |
SAN DIEGO, Sept. 16 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be
|
| Webcast Alert: Neurocrine Biosciences Announces 2nd Quarter 2009 Earnings Results |
30th July, 2009 |
Neurocrine Biosciences, Inc. |
SAN DIEGO, July 27 /PRNewswire-FirstCall/ -- Neurocrine Biosciences (Nasdaq: NBIX) announces the following Webcast:
What: Neurocrine Biosciences Webcast
When: July 30, 2009 @ 8:30am
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 58 individuals from Neurocrine Biosciences using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 511 times since April 2007, the link to the organisation's website has been followed 57 times Recent Search Terms used to find this page: chen chen neurocrine | Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix. | . Search for more companies in San Diego Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Neurocrine Biosciences |
